Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tizanidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 8/20 | 0.80 |
| ▸ | ADRA2B known ✓ | P18089 | 7/20 | 0.80 |
| ▸ | ADRA2C known ✓ | P18825 | 7/20 | 0.80 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.80 |
| ▸ | LMNA | P02545 | 4/20 | 0.80 |
| ▸ | NISCH | Q9Y2I1 | 3/20 | 0.80 |
| ▸ | HRH2 | P25021 | 2/20 | 0.80 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.48 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tizanidine SCHEMBL28208206 | 0.94 | ADRA2A (0.82) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL28207581 | 0.94 | ADRA2A (0.74) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL2472595 | 0.94 | ADRA2A (0.80) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL2472243 | 0.94 | ADRA2A (0.80) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL2471060 | 0.93 | ADRA2A (0.79) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL28207600 | 0.92 | ADRA2A (0.86) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL28156628 | 0.92 | ADRA2A (0.71) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL2474205 | 0.91 | ADRA2A (0.70) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL2469648 | 0.91 | ADRA2A (0.84) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL20769844 | 0.90 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524749-B2 | Administering a dosage form of 6-20 mg of tizanidine; plasma drug concentration substantially ascends over a period of 8 hours following administration | ALZA CORPORATION (US) | 2013-09-03 | — | — | US | claimed |
| US-20080214629-A1 | CONTROLLED RELEASE COMPOSITIONS OF TIZANIDINE | ALZA CORPORATION | 2008-09-04 | — | — | US | claimed |
| US-20080194655-A1 | ZERO ORDER CONTROLLED RELEASE COMPOSITIONS OF TIZANIDINE | ALZA CORPORATION | 2008-08-14 | — | — | US | claimed |
| WO-2008008394-A1 | TIZANIDINE SUCCINATE SALT FORMS AND METHODS OF MAKING AND USING THE SAME | TRANSFORM PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| EP-2370433-B1 | A METHOD FOR THE PREPARATION OF TIZANIDINE HYDROCHLORIDE | FARMAK A S (CZ) | 2014-05-14 | — | — | EP | disclosed |
| US-8487113-B2 | Method for the preparation of tizanidine hydrochloride | FARMAK, A.S. (CZ) | 2013-07-16 | — | — | US | disclosed |
| US-20110263863-A1 | METHOD FOR THE PREPARATION OF TIZANIDINE HYDROCHLORIDE | FARMAK, A.S. (CZ) | 2011-10-27 | — | — | US | disclosed |
| EP-2370433-A2 | A METHOD FOR THE PREPARATION OF TIZANIDINE HYDROCHLORIDE | Farmak, A.S. (CZ) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010069280-A2 | A METHOD FOR THE PREPARATION OF TIZANIDINE HYDROCHLORIDE | FARMAK, A.S. (CZ) | 2010-06-24 | — | — | WO | disclosed |
| WO-2008008394-A1 | TIZANIDINE SUCCINATE SALT FORMS AND METHODS OF MAKING AND USING THE SAME | TRANSFORM PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008394-A1 | TIZANIDINE SUCCINATE SALT FORMS AND METHODS OF MAKING AND USING THE SAME | TRANSFORM PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008394-A1 | TIZANIDINE SUCCINATE SALT FORMS AND METHODS OF MAKING AND USING THE SAME | TRANSFORM PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263863-A1 | METHOD FOR THE PREPARATION OF TIZANIDINE HYDROCHLORIDE | HRH2, HNMT, QDPR | ADRA2A 338/4885ADRA2B 429/4885ADRA2C 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.